title: Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications.
abstract: Carbamazepine and phenytoin, two of the most commonly prescribed antiepileptic drugs, have been proposed to share a similar mechanism of action by use-dependent inhibition of Na+ channels. The proposed similar mechanism of action, however, cannot explain the common clinical experiences that the two drugs are different; in some patients, one drug may be more effective than the other. This may occur even when optimal therapeutic concentrations are reached with both medications in plasma or the cerebrospinal fluid. In this study, we show that the action of the two drugs on Na+ channels are quantitatively very different. The affinity between inactivated Na+ channels and carbamazepine (apparent dissociation constant approximately 25 microM) is approximately 3 times lower than that of phenytoin, yet the binding rate constant of carbamazepine onto the inactivated Na+ channels is approximately 38,000 M(-1)/sec(-1), or approximately 5 times faster than that of phenytoin. It is speculated that carbamazepine may be more effective than phenytoin in treating seizures whose ictal depolarization shift is relatively short, whereas a better response to phenytoin may imply abnormal discharges characterized by more prolonged depolarization.
authors.affiliation: Department of Physiology, National Taiwan University College of Medicine, Taipei, Republic of China. cckuo@ntumcl.mc.ntu.edu.tw
authors.forename: C C
authors.initials: CC
authors.lastname: Kuo
authors.forename: R S
authors.initials: RS
authors.lastname: Chen
authors.forename: L
authors.initials: L
authors.lastname: Lu
authors.forename: R C
authors.initials: RC
authors.lastname: Chen
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D002220:Carbamazepine / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D006624:Hippocampus / Q000166:cytology; D007700:Kinetics; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology*; D010672:Phenytoin / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012964:Sodium / Q000378:metabolism / Q000502:physiology*; D026941:Sodium Channel Blockers; D015222:Sodium Channels / Q000378:metabolism / Q000502:physiology*
chemical_list: D000927:Anticonvulsants; D026941:Sodium Channel Blockers; D015222:Sodium Channels; D002220:Carbamazepine; D010672:Phenytoin; D012964:Sodium